Your browser doesn't support javascript.
loading
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer's disease.
Tropea, Maria Rosaria; Gulisano, Walter; Vacanti, Valeria; Arancio, Ottavio; Puzzo, Daniela; Palmeri, Agostino.
Afiliação
  • Tropea MR; Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, 95123, Italy.
  • Gulisano W; Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, 95123, Italy.
  • Vacanti V; Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, 95123, Italy.
  • Arancio O; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, USA; Department of Pathology & Cell Biology and Department of Medicine, Columbia University, New York, NY, 10032, USA.
  • Puzzo D; Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, 95123, Italy; Oasi Research Institute-IRCCS, Troina (EN), 94018, Italy. Electronic address: daniela.puzzo@unict.it.
  • Palmeri A; Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, 95123, Italy.
Free Radic Biol Med ; 193(Pt 2): 657-668, 2022 11 20.
Article em En | MEDLINE | ID: mdl-36400326
ABSTRACT
The nitric oxide (NO)/cGMP pathway has been extensively studied for its pivotal role in synaptic plasticity and memory processes, resulting in an increase of cAMP response element-binding (CREB) phosphorylation, and consequent synthesis of plasticity-related proteins. The NO/cGMP/CREB signaling is downregulated during aging and neurodegenerative disorders and is affected by Amyloidpeptide (Aß) and tau protein, whose increase and deposition is considered the key pathogenic event of Alzheimer's disease (AD). On the other hand, in physiological conditions, the crosstalk between the NO/cGMP/PKG/CREB pathway and Aß ensures long-term potentiation and memory formation. This review summarizes the current knowledge on the interaction between the NO/cGMP/PKG/CREB pathway and Aß in the healthy and diseased brain, offering a new perspective to shed light on AD pathophysiology. We will focus on the synaptic mechanisms underlying Aß physiological interplay with cGMP pathway and how this balance is corrupted in AD, as high levels of Aß interfere with NO production and cGMP molecular signaling leading to cognitive impairment. Finally, we will discuss results from preclinical and clinical studies proposing the increase of cGMP signaling as a therapeutic strategy in the treatment of AD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Idioma: En Ano de publicação: 2022 Tipo de documento: Article